JP2017513937A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513937A5
JP2017513937A5 JP2017504289A JP2017504289A JP2017513937A5 JP 2017513937 A5 JP2017513937 A5 JP 2017513937A5 JP 2017504289 A JP2017504289 A JP 2017504289A JP 2017504289 A JP2017504289 A JP 2017504289A JP 2017513937 A5 JP2017513937 A5 JP 2017513937A5
Authority
JP
Japan
Prior art keywords
seq
air marker
patient
antagonist
air
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2017504289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513937A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/052551 external-priority patent/WO2015155710A1/en
Publication of JP2017513937A publication Critical patent/JP2017513937A/ja
Publication of JP2017513937A5 publication Critical patent/JP2017513937A5/ja
Ceased legal-status Critical Current

Links

JP2017504289A 2014-04-11 2015-04-08 Il−13アンアゴニストを用いて喘息を選択的に治療する方法 Ceased JP2017513937A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461978604P 2014-04-11 2014-04-11
US61/978,604 2014-04-11
PCT/IB2015/052551 WO2015155710A1 (en) 2014-04-11 2015-04-08 Methods of selectively treating asthma using il-13 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019229495A Division JP2020079241A (ja) 2014-04-11 2019-12-19 Il−13アンアゴニストを用いて喘息を選択的に治療する方法

Publications (2)

Publication Number Publication Date
JP2017513937A JP2017513937A (ja) 2017-06-01
JP2017513937A5 true JP2017513937A5 (enExample) 2018-04-26

Family

ID=52997487

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017504289A Ceased JP2017513937A (ja) 2014-04-11 2015-04-08 Il−13アンアゴニストを用いて喘息を選択的に治療する方法
JP2019229495A Pending JP2020079241A (ja) 2014-04-11 2019-12-19 Il−13アンアゴニストを用いて喘息を選択的に治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019229495A Pending JP2020079241A (ja) 2014-04-11 2019-12-19 Il−13アンアゴニストを用いて喘息を選択的に治療する方法

Country Status (12)

Country Link
US (2) US10066267B2 (enExample)
EP (1) EP3129497B1 (enExample)
JP (2) JP2017513937A (enExample)
KR (1) KR20160138095A (enExample)
CN (1) CN106536754B (enExample)
AU (2) AU2015246037B2 (enExample)
BR (1) BR112016023238A2 (enExample)
CA (1) CA2943326A1 (enExample)
MX (1) MX2016013372A (enExample)
RU (1) RU2694980C2 (enExample)
TW (1) TW201542227A (enExample)
WO (1) WO2015155710A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7106788B2 (ja) 2016-07-08 2022-07-27 TAK-Circulator株式会社 Mex3b遺伝子の発現を抑制する核酸、mex3b遺伝子発現抑制剤、mex3b遺伝子発現を抑制する方法及びmex3b遺伝子発現に起因する疾病の予防又は治療剤
ES3041629T3 (en) * 2016-07-08 2025-11-13 Tak Circulator Corp Method for screening agents for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, tnf, g-csf, cxcl1, cxcl2, or cxcl5 and agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, tnf, g-csf, cxcl1, cxcl2, or cxcl5
US10650928B1 (en) * 2017-12-18 2020-05-12 Clarify Health Solutions, Inc. Computer network architecture for a pipeline of models for healthcare outcomes with machine learning and artificial intelligence
US10811139B1 (en) 2018-06-13 2020-10-20 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and dynamic patient guidance
US11763950B1 (en) 2018-08-16 2023-09-19 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and patient risk scoring
US11625789B1 (en) 2019-04-02 2023-04-11 Clarify Health Solutions, Inc. Computer network architecture with automated claims completion, machine learning and artificial intelligence
US11621085B1 (en) 2019-04-18 2023-04-04 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and active updates of outcomes
US11238469B1 (en) 2019-05-06 2022-02-01 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and risk adjusted performance ranking of healthcare providers
US10726359B1 (en) 2019-08-06 2020-07-28 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and automated scalable regularization
US10643751B1 (en) 2019-09-26 2020-05-05 Clarify Health Solutions, Inc. Computer network architecture with benchmark automation, machine learning and artificial intelligence for measurement factors
US10643749B1 (en) 2019-09-30 2020-05-05 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and automated insight generation
US11270785B1 (en) 2019-11-27 2022-03-08 Clarify Health Solutions, Inc. Computer network architecture with machine learning and artificial intelligence and care groupings
CN113215245A (zh) * 2021-05-21 2021-08-06 广州合一生物科技有限公司 一种用于儿童哮喘个体化用药的基因检测试剂盒及其应用
AU2021469707A1 (en) * 2021-10-22 2024-04-11 Illumina, Inc. Genotyping methods and systems
US12079230B1 (en) 2024-01-31 2024-09-03 Clarify Health Solutions, Inc. Computer network architecture and method for predictive analysis using lookup tables as prediction models

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
AU2750800A (en) 1999-02-01 2000-08-18 Amgen Canada Inc. Materials and methods to inhibit hodgkin and reed sternberg cell growth
US6645486B1 (en) 2000-01-25 2003-11-11 Ludwig Institute For Cancer Research Method of treatment with IL-9 conjugate
WO2003007685A2 (en) 2001-07-17 2003-01-30 University Of Florida Detecting and treating reproductive tract disorders
AU2002334969A1 (en) 2001-10-09 2003-04-22 Sylvie Barchechath Use of stat-6 inhibitors as therapeutic agents
CA2461665A1 (en) 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
JP2005512522A (ja) 2001-10-26 2005-05-12 セントカー・インコーポレーテツド Il−13ムテインタンパク質、抗体、組成物、方法および使用
US20040248260A1 (en) 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
JP2006520929A (ja) 2003-03-18 2006-09-14 日東電工株式会社 無定形フォトリフラクティブ材料の寿命を延長する方法
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
HRP20120376T1 (hr) * 2003-12-23 2012-05-31 Genentech Nova protutijela protiv il-13 i njihove upotrebe
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
DE602005025525D1 (de) 2004-11-17 2011-02-03 Amgen Inc Vollständige humane monoklonale antikörper gegen il-13
US20080044420A1 (en) 2005-05-11 2008-02-21 Heavner George A Anti-IL-13 antibodies, compositions, methods and uses
EP1942939B2 (en) 2005-09-30 2021-07-07 Medimmune Limited Interleukin-13 antibody composition
PT2532679T (pt) 2005-10-21 2017-07-18 Novartis Ag Anticorpos humanos contra il13 e utilizações terapêuticas
GB0600488D0 (en) 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
TW200804593A (en) 2006-01-24 2008-01-16 Domantis Ltd Fusion proteins that contain natural junctions
CA2679399A1 (en) 2007-02-27 2008-09-04 Genetech, Inc. Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
WO2011156000A2 (en) * 2010-06-07 2011-12-15 Aerovance, Inc. Use of il-4/il-13 antagonists to treat eosinophilic disorders
ES2645368T3 (es) 2010-10-15 2017-12-05 Medimmune Limited Terapias para mejorar la función pulmonar
KR101923282B1 (ko) 2010-12-16 2018-11-28 제넨테크, 인크. Th2 억제에 관한 진단 및 치료

Similar Documents

Publication Publication Date Title
JP2017513937A5 (enExample)
RU2016144177A (ru) Способы избирательного лечения астмы с использованием антагонистов il-13
KR101532797B1 (ko) 인터페론 알파 유도성 약력학적 마커
KR101719376B1 (ko) 연령-관련 황반 변성에서 유전자 다형성
JP5727484B2 (ja) I型インターフェロン診断法
JP5411129B2 (ja) インターフェロンα誘導性薬力学的マーカー
JP2013518590A (ja) TNF−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
Stoel et al. Restricted IgA repertoire in both B-1 and B-2 cell-derived gut plasmablasts
JP2015504430A5 (enExample)
US20150064193A1 (en) Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles
JP2017507130A5 (enExample)
US10617757B2 (en) Methods for treating multiple myeloma
CA2938731A1 (en) Methods of treating alzheimer's disease
Spindeldreher et al. T cell epitope mapping of secukinumab and ixekizumab in healthy donors
JP2022046486A (ja) 眼障害を治療する方法
JP2017519498A5 (enExample)
RU2014146594A (ru) Способы лечения анкилозирующего спондилита с использованием антагонистов il-17
KR20120089867A (ko) 연령-관련 황반 변성에서의 유전자 다형성
WO2014155278A2 (en) Methods of treating autoimmune diseases using il-17 antagonists
KR20200040803A (ko) 아토피 피부염의 치료 및 치료 선택을 위한 조성물 및 방법
US20240103001A1 (en) Markers for diagnosing infections
US10761098B2 (en) Methods and tools for Vel blood group typing
WO2002079503A1 (en) An allele of apolipoprotein e linked to neuropsychiatric disorders
HK1230521B (zh) 用於诊断和治疗炎症性肠病的方法